Alembic Pharmaceuticals Ltd. (APLLTD) — Tipsheet

Alembic eyes $259M cancer market with tentative US nod for Binimetinib

Tipsheet Editorial — Fri, 19 Jun 2026 13:50:40 GMT

Sole first applicant with Paragraph IV, Alembic qualifies for 180-day generic exclusivity on a melanoma and NSCLC drug. This is its largest single-product opportunity this year.

What’s new

Alembic received tentative US approval for generic Binimetinib 45 mg tablets, a kinase inhibitor used in melanoma and NSCLC.
The drug is a generic version of Array's Mektovi, with an estimated US market of $259M (₹2,150 cr).
As the sole first applicant with a Paragraph IV certification, Alembic is eligible for 180 days of marketing exclusivity upon final approval.

Why it matters

At ~29% of Alembic's annual revenue, this is a materially large opportunity. The 180-day exclusivity window gives Alembic a rare moat against competition, potentially securing a meaningful revenue stream in oncology, a high-value therapeutic area.

What we’re watching

Timeline of final approval — once granted, the exclusivity clock starts.
Whether any other filers challenge the Paragraph IV certification.
Launch execution and pricing strategy for a drug with a $259M market.

The full read

Alembic Pharmaceuticals has locked in a tentative US approval for generic Binimetinib 45 mg, a kinase inhibitor used in melanoma and NSCLC, and in doing so has secured a shot at the largest single-product opportunity it has seen this year. The drug targets a $259 million US market. Alembic is the sole first applicant with a Paragraph IV certification, which means once final approval comes, it will have 180 days of generic exclusivity. That is a rare moat. For context, $259 million (~₹2,150 cr) is about 29% of Alembic's annual revenue, far above the materiality threshold. The company now has 242 cumulative ANDAs, but this one stands apart. The next test: when final approval lands and whether Alembic can launch quickly to capture the exclusivity window.

Primary source: BSE · NSE

Alembic gets USFDA nod for generic Retin-A — but market is small

Tipsheet Editorial — Fri, 12 Jun 2026 12:47:00 GMT

The $76 million US market for Tretinoin Cream is less than 1% of Alembic's annual revenue, making this a routine pipeline addition.

What’s new

USFDA granted final approval for generic Tretinoin Cream 0.05%, a copy of Retin-A.
Addressable US market is $76 million, less than 1% of Alembic's ₹7,345 cr revenue.
Approval adds to the company's 242 ANDA pipeline but is below materiality threshold.

Why it matters

For a mid-cap pharma with a ₹14,581 cr market cap, a $76 million market is a rounding error. Routine approvals like this keep the pipeline fresh but don't shift earnings expectations. Alembic's recent 180-day exclusivity win on Larotrectinib was far more consequential.

What we’re watching

Timeline for commercial launch and potential market share capture.
Next major USFDA action on higher-value pipeline products.
Any update on the Canadian JV or Larotrectinib exclusivity launch.

The full read

Alembic Pharmaceuticals picked up another USFDA final approval, this time for generic Tretinoin Cream 0.05%, a copy of Retin-A. The US market is $76 million. For a company with trailing revenue of ₹7,345 crore, that is less than 1% of sales. It won't move the needle. This is a routine addition to a pipeline that already counts 242 ANDA approvals. It is genuinely new but not quantitatively significant. Alembic's more consequential recent wins, like the $91 million Larotrectinib approval with 180-day exclusivity, are what merit attention.

Primary source: BSE · NSE

Alembic lands 180-day exclusivity shot on $91m US cancer drug

Tipsheet Editorial — Thu, 11 Jun 2026 12:48:19 GMT

Tentative USFDA approval for the generic of Bayer's Vitrakvi makes Alembic the sole first applicant. The US market for the oncology drug is $91 million.

What’s new

Alembic got tentative USFDA approval for generic Larotrectinib, a kinase inhibitor for certain solid tumors with NTRK gene fusions.
The drug is the generic of Bayer's Vitrakvi, with an estimated US market of $91 million.
Alembic is the sole first-to-file applicant with a Paragraph IV certification, granting 180-day marketing exclusivity upon final approval.

Why it matters

This is Alembic's first major oncology win of scale. The $91 million US market for Larotrectinib is about 10% of Alembic's annual revenue of ₹7,345 cr, making it the most material single-product opportunity in the recent pipeline. The sole Paragraph IV status means no competition for six months once it launches.

What we’re watching

Final USFDA approval timing, which determines when Alembic can launch.
Competitor ANDA filings that could challenge the 180-day exclusivity window.
Sales ramp-up and pricing strategy for the oncology launch in the US.

The full read

Alembic Pharmaceuticals landed tentative USFDA approval for a generic version of Bayer's Vitrakvi, a targeted cancer drug. The US market for Larotrectinib capsules is estimated at $91 million, or about 10% of Alembic's annual revenue. Critically, Alembic is the sole first applicant with a Paragraph IV certification, securing a 180-day marketing exclusivity window once final approval is granted. The drug treats solid tumors with NTRK gene fusions. This is Alembic's most material single-product opportunity in the US market to date, far exceeding the scale of recent approvals like generic Haloperidol (a $27M market) or the Synthroid launch. The approval strengthens Alembic's oncology pipeline but remains tentative, meaning launch is not immediate. What changes from here is the timing of final clearance and the execution of the US rollout.

Primary source: BSE · NSE

Alembic takes 45% in new Canadian pharma JV with Difgen Holdings

Tipsheet Editorial — Sat, 06 Jun 2026 16:06:32 GMT

Alembic Pharmaceuticals is entering the Canadian market via a joint venture but won't say how much it's spending.

What’s new

Alembic signed a shareholders' agreement to acquire 45% of a newly incorporated Canadian corporation.
Difgen Holdings LLC holds an equal 45% stake; other parties hold the remaining 10%.
The venture will develop and commercialize pharmaceutical products in Canada.

Why it matters

Alembic is making its first direct move into the Canadian market, but the silence on deal size is notable. For a company with ₹7,345 crore in annual revenue, even a meaningful investment here would be a small fraction of its books, yet it sets a precedent for geographic expansion.

What we’re watching

The financial terms of the investment, which the filing does not disclose.
The new entity's first product pipeline or licensing deals.
Alembic's regulatory filings in Canada for the JV entity.

The full read

Alembic Pharmaceuticals is buying into Canada. The Indian drugmaker has signed a shareholders' agreement to take a 45% stake in a newly incorporated Canadian corporation, matching Difgen Holdings LLC's equal stake. The remaining 10% is held by other parties. The venture will develop and sell pharmaceuticals in Canada, and the new entity will become an associate of Alembic. The critical omission is the price. Without deal terms, investors cannot size the bet against Alembic's ₹7,345 crore in annual revenue. The filing is a strategic marker, not a financial one.

Primary source: BSE · NSE

Alembic lands generic Haldol approval, but the US market is tiny

Tipsheet Editorial — Fri, 05 Jun 2026 10:53:08 GMT

Final USFDA clearance for Haloperidol Tablets adds to a 240-product pipeline. The market it addresses is less than 3% of Alembic's revenue.

What’s new

USFDA granted final approval for Alembic's Haloperidol Tablets, a generic of Haldol.
The approved product addresses a US market worth about $27 million.
It is the 240th ANDA in Alembic's approved pipeline.

Why it matters

Alembic's annual revenue is ₹7,345 crore. The $27 million Haloperidol market, if fully captured, would represent less than 3% of that total. The approval keeps the pipeline machine running but doesn't change the company's earnings trajectory.

What we’re watching

The timing and scale of the product launch in the US.
Which ANDAs in the 240-product pipeline carry real commercial weight.
How Alembic's US base business performs against this low-bar addition.

The full read

Alembic Pharmaceuticals has received final USFDA approval to sell Haloperidol Tablets, a generic of Haldol. The product addresses a US market of $27 million (~₹224 crore). For a company with ₹7,345 crore in annual revenue, that's a potential contribution of less than 3%. This is Alembic's 240th approved ANDA. The number signals pipeline activity. Not a near-term financial boost. The approval is a routine pipeline addition, not an event that alters the company's earnings profile or valuation.

Primary source: BSE · NSE

Alembic lands US launch for generic Synthroid into a $1.87bn market

Tipsheet Editorial — Fri, 22 May 2026 11:00:14 GMT

Final USFDA approval lets Alembic sell immediately into the biggest thyroid-drug market in the US. The addressable market is more than double the company’s annual revenue.

What’s new

Alembic gets final USFDA approval for generic Levothyroxine Sodium, a copy of AbbVie's Synthroid.
The drug targets a US market worth $1.87 billion and can launch immediately.
It is the second major US approval in a short period, following a tentative nod for Darolutamide.

Why it matters

For a company with ~₹7,345 cr in annual revenue, even a sliver of a $1.87 billion market is a major earnings event. The final approval allows immediate launch, so revenue could appear as soon as the next quarter. The size of the market versus Alembic's own sales base makes this a forcing function for analyst model revisions.

What we’re watching

Initial market share and pricing Alembic can secure against established generic competitors.
Any paragraph IV litigation that could delay the launch.
How quickly this approval contributes to quarterly US revenue figures.

The full read

Alembic Pharmaceuticals can now sell a generic version of AbbVie's Synthroid in the US, entering one of the biggest drug markets it has ever tackled. The $1.87 billion addressable market for Levothyroxine Sodium tablets is more than double the company's own annual revenue of ₹7,345 crore. Even modest market share would move the needle on earnings. This is a final approval, so Alembic can launch immediately and start booking sales. It follows the tentative approval for Darolutamide, and bumps the company's total to 239 ANDAs, with 220 now final. For a mid-cap pharma, winning access to a nearly $2 billion product category is the kind of event that forces model revisions. The open question is how fast Alembic can commercialize against entrenched competitors.

Primary source: BSE · NSE

Alembic sets FY27 revenue growth target at low double digits

Tipsheet Editorial — Thu, 21 May 2026 15:31:38 GMT

Q4 FY26 conference call transcript confirms guidance for low double-digit revenue growth, R&D spend of ₹750-800 crore, and margin improvement.

What’s new

Transcript of Q4 FY26 earnings call confirms FY27 guidance.
Management expects low double-digit revenue growth and margin improvement.
No new material information beyond the live call.

Why it matters

The transcript is a routine record of already-disclosed guidance. Investors already heard the key points during the live call; the filing adds no new data. What matters is whether management delivers on the growth and margin targets laid out.

What we’re watching

Execution on US branded business and peptide pipeline
Ability to expand margins in FY27
Quarterly progress against the low double-digit growth target

The full read

Alembic Pharmaceuticals' Q4 FY26 earnings call transcript confirms management's FY27 outlook: low double-digit revenue growth, R&D spend of ₹750-800 crore, and expectations of margin improvement. The call also covered the US branded business and peptide pipeline in Q&A. However, the transcript is a procedural filing — the core information was disseminated during the live call on May 15, 2026. For investors, the open question is whether Alembic can execute on its guidance, not what the transcript says today.

Primary source: BSE · NSE